Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma

MYEOV and NEGR1 are novel candidate gene targets in neuroblastoma that were identified by chromosomal gain in 11q13 and loss in 1p31, respectively, through single nucleotide polymorphism array analysis. In the present study, to assess the involvement of MYEOV and NEGR1 in the pathogenesis of neuroblastoma, we analyzed their mutation status and/or expression profiles in a panel of 55 neuroblastoma samples, including 25 cell lines, followed by additional functional studies. No tumor‐specific mutations of MYEOV or NEGR1 were identified in our case series. Expression of MYEOV was upregulated in 11 of 25 cell lines (44%) and in seven of 20 fresh tumors (35%). The siRNA‐mediated knockdown of MYEOV in NB‐19 cells, which exhibit high expression of MYEOV, resulted in a significant decrease in cell proliferation (P = 0.0027). Conversely, expression studies of NEGR1 revealed significantly lower expression of this gene in neuroblastomas at an advanced stage of the disease. Exogenous NEGR1 expression in neuroblastoma cells induced significant inhibition of cell growth (P = 0.019). The results of these studies provide supporting evidence for MYEOV and NEGR1 as gene targets of 11q13 gains and 1p31 deletions in a neuroblastoma subset. In addition, the findings suggest a possible prognostic value for NEGR1 in neuroblastoma. (Cancer Sci 2011; 102: 1645–1650)

[1]  Mef Nilbert,et al.  Prognostic Impact of Array-based Genomic Profiles in Esophageal Squamous Cell Cancer , 2008, BMC Cancer.

[2]  The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients , 1998, Oncogene.

[3]  A. Jauch,et al.  Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). , 2000, Blood.

[4]  C. Bartram,et al.  Rearrangement and expression of myeov and hst in NIH/3T3 transfectants: a caveat for the interpretation of DNA transfection analyses. , 2007, Oncology reports.

[5]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[6]  P. Bates,et al.  OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer , 2003, Nature Genetics.

[7]  E. Schuuring,et al.  MYEOV: A candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer , 2002, International journal of cancer.

[8]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[9]  Y. Hayashi,et al.  Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma , 2001, Oncogene.

[10]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[11]  H. Gabra,et al.  The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates , 2005, Clinical Cancer Research.

[12]  T. Donohoe,et al.  Utility of the ammonia-free Birch reduction of electron-deficient pyrroles: total synthesis of the 20s proteasome inhibitor, clasto-lactacystin beta-lactone. , 2005, Chemistry.

[13]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[14]  R. Seeger,et al.  A surgical perspective on the current staging in neuroblastoma--the International Neuroblastoma Staging System proposal. , 1989, Journal of pediatric surgery.

[15]  André Scherag,et al.  Novel common copy number variation for early onset extreme obesity on chromosome 11q11 identified by a genome-wide analysis , 2010, Human molecular genetics.

[16]  P. Macmathuna,et al.  ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. , 2006, Biochemical and biophysical research communications.

[17]  S. Maekawa,et al.  Characterization of a Novel Rat Brain Glycosylphosphatidylinositol-anchored Protein (Kilon), a Member of the IgLON Cell Adhesion Molecule Family* , 1999, The Journal of Biological Chemistry.

[18]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[19]  H. Aburatani,et al.  Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma , 2004, Genes, chromosomes & cancer.

[20]  T. Rème,et al.  MYEOV is a prognostic factor in multiple myeloma. , 2010, Experimental hematology.

[21]  P. Macmathuna,et al.  MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2 , 2010, Journal of experimental & clinical cancer research : CR.

[22]  G. Brodeur Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.